[
  {
    "ts": null,
    "headline": "TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates",
    "summary": "TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.",
    "url": "https://finnhub.io/api/news?id=79db08340740f0f362379e4b46354c8189f0421a3c4e1d22d2c70ce9bd66475c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740760200,
      "headline": "TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates",
      "id": 132942931,
      "image": "https://media.zenfs.com/en/zacks.com/9137c6f6ed305652874fd6a3a724cf37",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.",
      "url": "https://finnhub.io/api/news?id=79db08340740f0f362379e4b46354c8189f0421a3c4e1d22d2c70ce9bd66475c"
    }
  },
  {
    "ts": null,
    "headline": "OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands",
    "summary": "The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.",
    "url": "https://finnhub.io/api/news?id=02eb2c684b2de23b7e59bb3ec56bd922c07391922a07bf6a043fe2a17a469962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740759660,
      "headline": "OPK Stock Gains Following Q4 Earnings Beat, Gross Margin Expands",
      "id": 132942932,
      "image": "https://media.zenfs.com/en/zacks.com/51f0c2cd09522c9a15cba48260e4facf",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "The strength in OPKO Health's transfer of intellectual property and other revenues boosts its overall fourth-quarter 2024 performance despite lower RAYALDEE sales.",
      "url": "https://finnhub.io/api/news?id=02eb2c684b2de23b7e59bb3ec56bd922c07391922a07bf6a043fe2a17a469962"
    }
  },
  {
    "ts": null,
    "headline": "Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes",
    "summary": "TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.",
    "url": "https://finnhub.io/api/news?id=1f6894cb015ba02e606d384776fc70d048bf53513e16b0b51a5a0f18658c5af6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740753600,
      "headline": "Teleflex Stock Rises on Q4 Earnings Beat, Gross Margin Crashes",
      "id": 132942933,
      "image": "https://media.zenfs.com/en/zacks.com/62a1df11c94046acffed2654620317fb",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.",
      "url": "https://finnhub.io/api/news?id=1f6894cb015ba02e606d384776fc70d048bf53513e16b0b51a5a0f18658c5af6"
    }
  },
  {
    "ts": null,
    "headline": "Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract",
    "summary": "CHE's earnings and revenues beat estimates in the fourth quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=6e8141b48320e3bbaa3232876c48714b23fedf4ac35b8691af0ff481359d7a63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740749400,
      "headline": "Chemed Q4 Earnings & Revenues Top, Stock Climbs, Margins Contract",
      "id": 132942934,
      "image": "https://media.zenfs.com/en/zacks.com/3112121c6d76ba5c9f90e48257faae0a",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "CHE's earnings and revenues beat estimates in the fourth quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=6e8141b48320e3bbaa3232876c48714b23fedf4ac35b8691af0ff481359d7a63"
    }
  },
  {
    "ts": null,
    "headline": "ResMed (NYSE:RMD) shareholders have earned a 7.2% CAGR over the last five years",
    "summary": "If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...",
    "url": "https://finnhub.io/api/news?id=65505f8c513d281944db99e84845d0066bf856051c84c4d4cc8ed97eb27bd8c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740740448,
      "headline": "ResMed (NYSE:RMD) shareholders have earned a 7.2% CAGR over the last five years",
      "id": 132942935,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9",
      "related": "RMD",
      "source": "Yahoo",
      "summary": "If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...",
      "url": "https://finnhub.io/api/news?id=65505f8c513d281944db99e84845d0066bf856051c84c4d4cc8ed97eb27bd8c6"
    }
  }
]